Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications is open for enrollment; continue to expect to dose...
The clinical-stage biotech saw a slight bounce-back from its lows of last week.
In trading on Thursday, shares of ZIOPHARM Oncology Inc touched a new 52-week low of $1.26/share. That's a $4.69 share price drop, or -78.82% decline from the 52-week high of $5.95 set back on 02/10/2021....
HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the presentation of...
BOSTON (AP) _ Ziopharm Oncology Inc. (ZIOP) on Monday reported a loss of $22.7 million in its third quarter.
HOUSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced financial results for...
HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it will report...
• Over 50% reduction in personnel
BOSTON and HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that Kevin S. Boyle, Sr., Chief Executive Officer...
Mr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership roles